Currently Viewing
FDA Grants Accelerated Approval to Astellas
January 14, 2020
Bladder Cancer Advocacy Network Turns 15
January 10, 2020 – Bladder Cancer Advocacy Network
Lung Cancer Registry Launches New Surveys
December 13, 2019 – GO2 Foundation for Lung Cancer
4th Annual 'Scott Hamilton and Friends' Benefits The Scott Hamilton CARES Foundation for Funding Cancer Research with Partial Proceeds Benefiting the V Foundation for Cancer Research
November 22, 2019 – V Foundation
Age Bias is a Problem for Patients With Breast Cancer
November 22, 2019 – Susan G. Komen NYC
AIM at Melanoma Opens Third Branch of Fresh Frozen Primary Tissue Bank at the Knight Cancer Institute at Oregon Health & Science University
November 19, 2019 – AIM at Melanoma
Finding Support in a 'Cancer' Family
November 19, 2019 – Kristi Sabbides
Reimagining the Possible: A 20-Year Survivor of Pancreatic Cancer
November 18, 2019 – Lets Win! Pancreatic Cancer
Hope on the Horizon
November 18, 2019 – Lets Win! Pancreatic Cancer

FDA Grants Accelerated Approval to Astellas

FDA has given an accelerated approval to Padcev in the treatment of patients with locally advanced or metastatic urothelial cancer.
PUBLISHED January 14, 2020
The U.S. Food and Drug Administration announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval to PADCEV™ for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1 inhibitor and a platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery or in a locally advanced or metastatic setting.

PADCEV is approved under the FDA’s Accelerated Approval Program based on tumor response rate.

Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Read Seattle Genetics’ and Astellas’s press release here.

 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Bladder Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In